Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2).

Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2). - Immune checkpoint status and oncogenic mutation profiling of rectal cancer after neoadjuvant chemotherapy (KSCC1301-A2).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000031045

Enrollment

147

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: KSCC participants As control arm, 37 rectal cancer patients who underwent surgery at our hospital without neoadjuvant therapy.

Exclusion criteria

Exclusion criteria: Same as KSCC1301(UMIN000011486)

Design outcomes

Primary

Measure	Time frame
PD-L1 expression status among rectal cancer patients after neoadjuvant chemotherapy.	—

Countries

Japan

Contacts

Public ContactYu Miyashita

Graduate School of Medical Sciences, Kyushu University Department of Surgery and Science

miya_y@surg2.med.kyushu-u.ac.jp092-642-5466

Outcome results